Delivery Order SPE2DB22D1106-SPE2DB25FFBX1
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $41,926.54 for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) on August 21, 2025, with completion scheduled for August 22, 2025. This is a firm fixed-price, non-set-aside award that represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be...
- The Defense Logistics Agency awarded a $50,306.61 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This non-competitive delivery order, which is scheduled for completion by August 29, 2025, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $5,773.90 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count) on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price delivery order, issued without a set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $16,076.36 to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalers (60-count) on September 12, 2025, with an ultimate completion date of September 15, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalers (60-count units) with a ceiling value of $1,867.66 and an ultimate completion date of August 1, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was made...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalers (60-count units) with a ceiling value of $1,661.80. This firm fixed-price delivery order, which is not set-aside, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance...
- The Defense Logistics Agency awarded a delivery order valued at $41,772.77 to AmerisourceBergen Drug Corp for the supply of Trelegy Ellipta 200-62.5-25 inhalers (60-count packages), with a completion date of September 2, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999.99 million...
- The Defense Logistics Agency awarded a $57,155.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) on August 11, 2025, with completion targeted for August 12, 2025. This competitively awarded, non-set-aside contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $5,007.60 delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The point of performance is...
- The Defense Logistics Agency awarded a $31,540.49 delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of May 13, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor and...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFBX1Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalers (60-count units) valued at $101,693.21. This firm fixed-price delivery order, with an ultimate completion date of August 7, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation. Trelegy Ellipta is a combination maintenance inhaler used to treat chronic obstructive pulmonary disease, demonstrating the breadth of pharmaceutical products AmerisourceBergen supplies to support military and federal healthcare systems. This delivery order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company operates as one of the nation's largest pharmaceutical distributors. The delivery order is issued under AmerisourceBergen's comprehensive DLA contract vehicle (SPE2DX) valued at $999,999,999.00 through December 2026, which enables the company to supply pharmaceuticals, vaccines, and medical supplies globally to support Defense Health Agency programs and other federal healthcare systems. The non-set-aside competitive award reflects AmerisourceBergen's established capability to meet federal procurement standards for critical pharmaceutical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $101.7k | 8/6/25 |